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In 1976, two outbreaks of a previously 
unknown disease occurred almost 
simultaneously in northern Zaire (now 
Democratic Republic of Congo) and southern 
Sudan. They were dramatic: Most of those 
afflicted died, often with severe haemorrhagic 
disease; the disease spread to family members 
and other close contacts; and dramatically also 
in and through healthcare settings. (Peter Piot 
provides a vivid account of events in his book 
"No time to lose" (1).) Two different 
filoviruses, Zaire ebolavirus and Sudan 
ebolavirus, were identified as aetiological 
agents.  
The evolutionary origin of Ebolaviruses is not 
very clear. The simple notion that these viruses 
have been circulating for many millennia in 
wildlife in tropical parts of Africa, 
occasionally spilling over into human 
populations, often brought on by human 
activities, may not be correct or at least 
incomplete (2,3). 
 
Since then there have been a number of Ebola 
disease outbreaks reported (4). Over time, a 
pattern in the outbreak response seemed to 
have been established, consisting of relatively 
prompt notification and deployment of 
specialised teams, typically provided by 
Médecins Sans Frontières (5) (MSF, Doctors 
Without Borders) and other NGOs with 
support from agencies such as the World 
Health Organization (WHO), the U.S. Centres 
for Disease Control and Prevention (CDC) etc. 
These efforts typically succeeded in bringing 
the outbreak under control through measures 
including adequate precautions against blood-
borne virus transmission, quarantining of 
exposed individuals, isolation units for treating 
the diseased, etc. (6,7). 
 
A lot was also learnt about Ebolaviruses, their 
epidemiology and ecology: The natural 
reservoir seem to be frugivorous bats (8,9); 
outbreaks pose an acute threat not only to 
human beings but also to Great Apes (10); 
their geographic distribution extends beyond 
Central and East Africa:            ebolavirus 
occurs in Côte d'Ivoire (Ivory Coast) and 
Reston ebolavirus in the Philippines (with 
importation from there into the USA and 
Italy); Reston ebolavirus causes asymptomatic 
infection in human beings and can infect pigs; 
and in 2007, a fifth Ebolavirus species, 
Bundibugyo, was discovered in Uganda (11). 
 
However, the 2014 Ebola outbreak challenges 
our understanding in many respects. It started 
in Guinée forestière (Forested Guinea) in West 
Africa, far away from regions previously 
known to harbour Ebola viruses, toward the 
end of 2013, apparently through one zoonotic 
transmission event followed by generation 
upon generation of human-to-human 
transmission (12). Whether human influences 
may be to blame is being disputed (13). The 
outbreak has so far (as of 2
nd
 September 2014) 
spread to Sierra Leone, Liberia and Nigeria, 
with most recently an imported case being 
reported from Senegal. 
 
The outbreak is continuing and clearly out of 
control. The number of probable and 
confirmed cases is 3069, with 1552 deaths, but 
there are fears that many cases go unreported. 
Its burden is already greater than that of all 
previous outbreaks combined, and no end is in 
sight: Over 40% of cases have occurred within 
the past 3 weeks (14).   
 
Sadly, neither Liberia (1378 cases with 694 
deaths) nor Sierra Leone (1026 cases with 422 
deaths) were able to learn from the events 
unfolding over months just across their borders 
in Guinea (648 cases with 430 deaths) and now 
carry the greatest burden. Especially 
troublesome is the high number of infected 
health care workers (more than 240 of whom 
about half have died), leaving already 
struggling health care systems even worse off. 
However, this does not mean that established 
infection control measures are insufficient; a 
lack of personal protective equipment, its 
improper use, and the sheer burden of many 
critically ill patients and far too few staff 
account for this tragedy. That a single infected 
traveller from Liberia to Nigeria caused 17 
direct and subsequent transmissions points to 
serious flaws with applying very basic 
protective measures. 
 
While MSF had repeatedly issued dire 
warnings months ago already, official agencies 
were overly complacent. It seems that only the 
medical evacuations of several foreigners to 
their home countries served as wake-up calls to 
 
 
the international community. While this is 
useful in that finally sufficient resources are 
being devoted to the issue, the sense of panic 
about the possible importation and subsequent 
spread of Ebola virus in industrialised 
countries is unjustified and counterproductive 
(as so beautifully expressed by Zapiro recently 
(15)). 
 
Apart from a belated and panic-driven 
response, there is a very active discussion of 
specific treatment options. Ebola is a classical 
neglected tropical disease; these diseases occur 
in resource-poor settings and thus offer little 
financial incentives for research and 
development to be undertaken by drug 
companies, as the vast majority of those who 
would benefit from such drugs would not be 
able to afford them. Luckily though (odd as it 
may sound), filoviruses are regarded as 
potential biowarfare or bioterrorism agents 
under the highest priority Category A (16) 
which has triggered major government 
investment into vaccine and drug development 
(17). This is at the origin of many of the 
treatment modalities  currently being discussed 
and, in some cases, even administered 
although none of these has undergone a phase 
3 clinical trial. However, most of these 
discussions do not take cognisance of the 
extremely limited clinical care most Ebola 
patients currently receive which certainly 
contributes to the high fatality rate. This needs 
to be addressed and improved very urgently, 
not least to increase community confidence in 
the health care system (18-20)). Furthermore, 
it is also sad that although after the SARS 
outbreak in 2003 (21), the "swine 'flu" 
pandemic of 2009, and on other occasions, 
there have been discussions around the need to 
prepare in advance so that controlled clinical 
trials can be instituted rapidly once outbreak 
situations occur, none of this seems to have 
been translated into practice (22). In any case, 
the key to controlling the outbreak will not lie 
in providing specific therapies (even if safe 
and effective) to a few (for sufficient quantities 
of these compounds will not be available for 
months to come) but in implementing an 
effective response as outlined in WHO's 
"roadmap" (23). 
 
The magnitude and propensity to spread of the 
current outbreak have been seriously 
underestimated (24). Most experts expect it to 
get a lot worse before it will be brought under 
control. Missed opportunities abound. Lack of 
preparation for the event of cases reaching 
industrialised or middle income countries such 
as South Africa is not one of them. Although 
one can never exclude the possibility of limited 
onward transmission, especially when the 
index patient's Ebola diagnosis is not made in 
time, it is highly unlikely that even such an 
unfortunate event would result in a larger 
outbreak. While the recent events in Nigeria 
may serve as a warning I believe that places 
like Cape Town are as safe as most European 
or American cities, as long as complacency 
does not set in. 
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